News

The study identified 2 fungal profiles in AD patients, with 1 subgroup exhibiting distinct fungal dysbiosis.

Asha Patel Shah, MD, MBA, FAAD, discusses recent research on retinol and retinoid bioactivity when layered with moisturizers highlighted at AAD 2025.

Participants from the parent DELTA 1 and 2 studies maintained their disease control and observed a decrease in pain and itch over 52 weeks of treatment.

Researchers have identified elevated eosinophil levels as a potential marker for chronic urticaria in pediatric patients.

At the 2025 AAD Annual Meeting, Alumis Inc. presented promising phase 2 STRIDE trial results for ESK-001, a TYK2 inhibitor showing sustained psoriasis improvements over 52 weeks.

As a featured clinician in EltaMD’s Derm Day campaign, Mona Gohara, MD, spoke about her connection with the brand and the work being done to unify dermatologists and promote skin health.

The lowest-dose oral minocycline for rosacea is now available by prescription following FDA approval in November 2024.

CBD skin care is booming, but are patients getting real benefits? Learn about CBD legality, safety, and potential dermatologic effects.

Explore the top headlines of the week including insights on voluntary recalls, DIMIDs and pandemic risks, and AAD pearls.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

In case you missed it, this week we had news about positive results from Incyte’s phase 3 STOP-HS trials, multidisciplinary approaches to advanced BCC and CSCC, pediatric ocular adverse effects associated with dupilumab, and more.

This week, we feature top articles from our sister publications on long COVID recovery, integrating AI into pharmacy, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Eve Arnera and Thandiwe Munaiwa, MD, spoke about the groundbreaking collaboration between SkinCeuticals and ReSurge International, “Pioneering Women in Reconstructive Surgery.”

At week 24, the proportion of Asian patients achieving significant hair regrowth (SALT ≤20) was substantially higher in ritlecitinib treatment groups than in placebo groups.

Participants reported increased confidence in clinical interactions and greater interest in dermatology as a career path.

In part 2 of this Frontline Forum supplement, experts discuss current and emerging treatments, digital tools and supports, and more.

The 730-nm picosecond laser had an efficacy rate of 88% with higher patient satisfaction compared to the 1604-nm wavelength.

Estrogen therapy and certain diuretics may increase skin cancer risk, highlighting the need for careful patient counseling and sun exposure management.

Key estate planning changes in 2025: potential tax law shifts, federal exemption sunset, retirement account rules, state death taxes, and cryptocurrency issues.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

The review also found that female patients with non melanoma skin cancer demonstrated a greater risk of completed suicide compared to members of a control group.

Nail psoriasis affects 50% of plaque psoriasis patients, making effective treatments crucial.

This real-world data explores the use of the IL-17A blocker for up to 3 years in several subtypes of psoriasis.

A recent study highlights the need for ophthalmologic monitoring in pediatric dupilumab therapy.

The phase 1a study is a first in-human trial evaluating SYX-5219 for AD.

John Strasswimmer, MD, PhD, spoke on the difficulty of managing adverse effects, the role of interdisciplinary clinical relationships, and the challenges in complex and older patients.

A 30-year-old patient with dermatofibrosarcoma protuberans faced a recurrence after initial surgery. Mohs micrographic surgery was used for precise excision, reducing recurrence risk and improving outcomes.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Tezepelumab reduced CSU activity post-treatment through week 32, suggesting a delayed, sustained TSLP blockade effect.